In this presentation from Pediatric Ophthalmology Subspecialty Day 2022, Dr. Michael Repka discusses digital therapeutics, a new class of software-driven interventions intended to treat various medical conditions. His focus is the review of a randomized controlled trial of the Luminopia dichoptic digital therapeutic in young children with amblyopia. Dr. Repka also briefly reviews data for the CureSight digital therapy device (NovaSight) for amblyopia, which uses anaglyphic glasses and a screen instead of a virtual reality headset. He concludes that study results support the use of a digital therapeutic as an alternative to patching or atropine.